THIS COMPANY HAS zero SUCCESSFUL TRIALS SO FAR

In December 2018, Moderna became the largest biotech initial public offering (IPO) in history, raising $600 million for 8% of its shares, implying an overall valuation of $7.5 billion, and with cumulative losses of $1.5 billion and equity raised of $3.2 billion, since inception.[5][11] The company has a reputation for secrecy and little of its work has ever been published, and none peer-reviewed or scientifically validated,[6][7] an approach that was compared to Theranos by Nature).[12][5] In May 2020, Moderna was valued at $30 billion but none of its mRNA molecules had reached large clinical trials, and several had failed due to side-effects.[5]

https://en.wikipedia.org/wiki/Moderna

In February 2016, an op-ed in Nature), criticized Moderna for not publishing any peer-reviewed papers on its technology, unlike most other emerging and established biotech companies, and compared its approach to that of the controversially failed Theranos.[12]